Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Français Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Potential Interaction

Ritonavir (RTV)

_Telaprevir

Quality of Evidence: Low

Summary:

Coadministration of single doses of ritonavir and telaprevir increased telaprevir Cmax (30%) and AUC (2-fold). However, multiple dose studies showed telaprevir Cmax, Caverage and Cmin decreased by 15%, 24% and 32%, respectively (when compared to telaprevir 750 mg every 8 hours alone).

Description:

Coadministration of ritonavir (100 mg single dose) and telaprevir (750 mg single dose) to 14 subjects increased telaprevir Cmax by 30% and AUC by 2-fold. A multiple dose study in 5 subjects of ritonavir (100 mg twice daily) and telaprevir (750 mg twice daily) decreased telaprevir Cmax, Caverage and Cmin by 15%, 24% and 32%, respectively (when compared to telaprevir 750 mg every 8 hours alone).
Incivek Prescribing Information, Vertex Pharmaceuticals Inc, June 2012.
 
The effects of low dose ritonavir on the pharmacokinetics of telaprevir were determined in three groups of HIV-negative subjects (n=6 per group).  Subjects received telaprevir alone (750 mg every 8 h) or telaprevir (250 mg or 750 mg twice daily) with ritonavir (100 mg twice daily).  Following multiple doses of telaprevir and ritonavir, no significant boosting of telaprevir exposure by ritonavir was observed. When given with ritonavir, the Cmax and Cmin of the lower telaprevir dose decreased by 59% and 74%, respectively compared to telaprevir alone: Cmax and Cmin of the higher telaprevir dose decreased by 15% and 32%.
Low dose ritonavir and the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers. Garg V, et al. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011, Abstract 629.

View all available interactions with Ritonavir (RTV) by clicking here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2025 The University of Liverpool. All rights reserved.